

<b>Date of the CVA</b>	18/01/2021
------------------------	------------

## Section A. PERSONAL DATA

Name and Surname	JOSÉ ALCAMÍ PERTEJO		
DNI/NIE/Passport		Age	
Researcher's identification number	Researcher ID		
	Scopus Author ID	7004011032	
	ORCID	0000-0003-0023-7377	

\* Obligatorio

### A.1. Current professional situation

Institution	Institut d'Investigacions Biomèdiques August Pi i Sunyer		
Dpt. / Centre	Infecciosas / Hospital ClinicInfecciosas		
Address			
Phone		Email	
Professional category	Director Científico	Start date	2019
Keywords			

### A.2. Academic education (Degrees, institutions, dates)

Bachelor/Master/PhD	University	Year
Doctor en Medicina	Universidad Complutense de Madrid	1994
Diplôme d' Immunopatologie	Instituto Pasteur de Paris	1990
Medicina	Universidad Autónoma de Madrid	1980

### A.3. General quality indicators of scientific production

Research Professor, the highest degree of the research career in Spain. Awarded with 30 years of excellency in Research

Director of 9 PhD Thesis

Indexed publications in scientific journals: 190 (>75% in Q1)

Total number of cites 6.430 (6.067 without self-citations)

h index = 44

Book chapters and dissemination articles: 90

Four patents

## Section B. SUMMARY OF THE CURRICULUM

Dr José (Pepe) Alcamí is MD and PhD in molecular microbiology by University of Madrid. He is specialist in Internal Medicine (1982-1986) and Fellowship in Immunology by Hospital 12 de Octubre (1986-1988) and Pasteur Institute (1991). Associated researcher at Viral Immunology Unit at Pasteur Institute between 1988-1992 he returned to Spain in 1992 and was appointed as director of the Viral Immunology Unit at Hospital 12 de Octubre and head of the Molecular Virology section.

Dr Alcamí is an expert in HIV pathogenesis, in particular in the mechanisms involved in HIV latency and viral entry. Besides, his group has developed new strategies to tackle HIV infection in the field of anti-latency drugs, microbicides and has developed new prototypes of preventive HIV vaccines. Currently he is Research Professor and leads the AIDS Immunopathogenesis Unit (IP-LAB, <http://hiv-lab.com/>) at Instituto de Salud Carlos III, one of the most important basic research groups in the HIV field in Spain. With 20 researchers, the IP-LAB addresses different aspects of HIV pathogenesis, drug discovery and vaccine development. In these fields the laboratory has developed new strategies to target the HIV reservoirs aiming at a functional cure and is a reference group in the development and testing of HIV vaccines. The group is member of several European Networks in the field of microbicides and vaccines. Since 2003 is coordinator of the Spanish AIDS Research Network that brings together the research of 40 different groups working in basic, clinic and epidemiological research. Since 2019 Dr Alcamí

has been appointed as Scientific Director of the HIV Unit at Hospital Clinic, Barcelona, Spain an activity that shares with his position at Instituto Carlos III and that allows the development of intensive clinical research in collaboration with investigators from Hospital Clinic.

He is author of more than 190 publications in high rank journals including J Virology, Nature Reviews in Microbiology, Nature, J Infectious Diseases, AIDS, Plos Biology, Cell Reports and Retrovirology. Is consultant for different journals in the field of virology, immunology and pharmacology, associated editor of J Virology and scientific advisor of the European Commission, the INSERM, the French Agency for AIDS Research and Spanish scientific institutions. Dr Alcamí is advisor of the European and Spanish Medicines Agencies, and has been member of the Scientific advisory Board of Centre for Genetic Research in Montpellier, Hospital Ramón y Cajal and 12 de Octubre in Madrid and ISGlobal here in Barcelona.

He carries scientific collaborations with Pasteur Institute (Paris), Imperial College (London), Università San Raffaele (Milan), Vaccine Research Centre (NIH), Utah University (EEUU), Institute of Human Genetics (Montpellier) and Ramón y Cajal (Madrid) among others.

He has been full professor of Immunology and Virology at European University of Madrid and currently is the director of the Master of Infectious Diseases at University of Alcalá de Henares.

He has organized the AIDS Conference in 2002 as chair of the Basic Science Track and has been Chair of the Research for Prevention meeting held in Madrid in 2018.

## Section C. MOST RELEVANT MERITS (ordered by typology)

### C.1. Publications

AC: Autor de correspondencia; (n° x / n° y): posición firma solicitante / total autores

- 1 Scientific paper.** Díez-Fuertes Francisco; Iglesias Caballero María; García-Perez Javier; et al; (AC);. (14/15). 2020. A FOUNDER EFFECT LED EARLY SARS-COV-2 TRANSMISSION IN SPAIN. J Virol.95-3, pp.e0158320-20.
- 2 Scientific paper.** Abdel-Mohsen, Mohamed; Richman, Douglas; Siliciano, Robert F.; et al; Alcamí, Jose; BEAT HIV Delaney Collaborator. (11/34). 2020. Recommendations for measuring HIV reservoir size in cure-directed clinical trials NATURE MEDICINE. NATURE PUBLISHING GROUP. 26, pp.1339-1350. ISSN 1078-8956.
- 3 Scientific paper.** Pothlichet, Julien; Rose, Thierry; Bugault, Florence; et al; Alcamí, Jose; Theze, Jacques. (9/13). 2020. PLA2G1B is involved in CD4 anergy and CD4 lymphopenia in HIV-infected patients JOURNAL OF CLINICAL INVESTIGATION. AMER SOC CLINICAL INVESTIGATION INC. 130-6, pp.2872-2887. ISSN 0021-9738.
- 4 Scientific paper.** Díez-Fuertes, F.; De La Torre-Tarazona, H. E.; Calonge, E.; et al; Alcamí, J. (AC). (17/17). 2020. Association of a single nucleotide polymorphism in the ubxn6 gene with long-term non-progression phenotype in HIV-positive individuals CLINICAL MICROBIOLOGY AND INFECTION. ELSEVIER SCI LTD. 26-1, pp.107-114. ISSN 1469-0691.
- 5 Scientific paper.** Díez-Fuertes F; De La Torre-Tarazona HE; Calonge E; et al; Alcamí J (AC). (9/9). 2019. Transcriptome Sequencing of Peripheral Blood Mononuclear Cells from Elite Controller-Long Term Non Progressors. Scientific Report. 9(1):14265.
- 6 Scientific paper.** Rodríguez-Mora, Sara; De Wit, Flore; Garcia-Perez, Javier; et al; Alcamí, Jose (AC). (14/14). 2019. The mutation of Transportin 3 gene that causes limb girdle muscular dystrophy 1F induces protection against HIV-1 infection. PLoS pathogens. 15-8, pp.e1007958. ISSN 1553-7374.
- 7 Scientific paper.** Sliepen, Kwinten; Han, Byung Woo; Bontjer, Ilja; et al; Alcamí, Jose; Sanders, Rogier W.(23/35). 2019. Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence NATURE COMMUNICATIONS. NATURE PUBLISHING GROUP. 10. ISSN 2041-1723.
- 8 Scientific paper.** Bedoya, LM.; Beltrán, M.; Obregón Calderón, P.; et al; Alcamí, J. (AC). (11/11). 2016. Hydroxytyrosol: a new class of microbicide displaying broad anti-HIV-1 activity. AIDS (London, England). 30-18, pp.2767-2776. ISSN 1473-5571.

- 9 **Scientific paper.** Coiras, M.; Bermejo, M.; Descours, B.; et al; Alcamí, J. (AC). (9/9). 2016. IL-7 Induces SAMHD1 Phosphorylation in CD4+ T Lymphocytes, Improving Early Steps of HIV-1 Life Cycle. Cell reports. 14-9, pp.2100-2107. ISSN 2211-1247.
- 10 **Scientific paper.** Coiras M; López-Huertas MR; Pérez-Olmeda M; Alcamí J. (AC). (4/4). 2009. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nature reviews. Microbiology. 7, pp.798-812. ISSN 1740-1526.

## C.2. Participation in R&D and Innovation projects

- 1 Seguridad, tolerancia y actividad antirretroviral de dasatinib: estudio clínico piloto en pacientes con infección reciente por el VIH-1 (Proyecto DASA HIVCURE). JOSE MARIA MIRO MEDA. (Institut d'Investigacions Biomèdiques August Pi i Sunyer). 01/01/2021-31/12/2023. 664.690 €. Co-IP, Coordinador Work Package.
- 2 GRANT NUMBER: 1R01AI143567-01 / FAIN: R01AI143567, TYROSINE KINASE INHIBITION: THE NEW FRONT IN HIV CURE EFFORTS. NIH. MARIA TERESA COIRAS LOPEZ. (Instituto de Salud Carlos III). 07/11/2018-31/10/2023. 598.181 €. Co-Investigador Principal.
- 3 MECANISMOS CELULARES IMPLICADOS EN LA RESTRICCIÓN Y PROGRESIÓN DE LA INFECCIÓN POR EL VIH. FIS-ISCIII. JOSE ALCAMI PERTEJO. (Instituto de Salud Carlos III). 01/01/2020-31/12/2022. 237.000 €.
- 4 MECHANISMS OF HIV-1 RESISTANCE IN PATIENTS WITH A RARE MUSCULAR DYSTROPHY DUE TO A MUTATION IN THE TNPO3 GENE ANRS. JOSE ALCAMI PERTEJO. (Instituto de Salud Carlos III). 01/07/2020-30/06/2022. 99.900 €.
- 5 RED ESPAÑOLA DE INVESTIGACIÓN EN SIDA (RIS) JOSÉ ALCAMÍ PERTEJO. (Instituto de Salud Carlos III). 01/01/2017-31/12/2021. 743.136 €. Co-ordinator.
- 6 ENSAYO CLÍNICO ALEATORIZADO MULTICÉNTRICO DE TERAPIA CON PLASMA DE CONVALECIENTES AÑADIDO AL MEJOR TRATAMIENTO DISPONIBLE PARA COVID-19. JOSE ALCAMI PERTEJO. (Instituto de Salud Carlos III). 01/05/2020-31/05/2021. 50.000 €.
- 7 EAVI 2020: EUROPEAN AIDS VACCINE INITIATIVE 2020 UNIÓN EUROPEA. JOSÉ ALCAMI PERTEJO. (Instituto de Salud Carlos III). 01/11/2015-01/11/2020. 404.328,75 €. Co-ordinator.
- 8 CHARACTERIZATION OF THE HIV RESERVOIR DISPLAYING LOW LEVEL REPLICATION THROUGH SINGLE CELL ANALYSIS IN DIFFERENT LYMPHOID SUBPOPULATIONS. 6ª Convocatoria de Becas Gilead a la Investigación 2018 en VIH, Hepatitis y Hemato-oncología. JOSE ALCAMI PERTEJO. (Instituto de Salud Carlos III). 01/01/2019-31/12/2019. 44.821 €. Principal investigator.
- 9 U.E. 242135, CHAARM: COMBINED HIGHLY ACTIVE ANTI-RETROVIRAL MICROBICIDES UE. HEALTH 2009-2.3.2-3. JOSÉ ALCAMÍ PERTEJO. (Instituto de Salud Carlos III). 31/10/2010-30/06/2015. 300.000 €. Principal investigator.
- 10 U.E. 305938, AIM-AIV: HYDROXITIRO SOL, A NEW GENERATION OF MICROBICIDES TARGETING HIV THROUGH ANTIVIRAL AND ANTI-INFLAMMATORY PATHWAYS UE. JOSÉ ALCAMI PERTEJO. (Instituto de Salud Carlos III). 01/12/2012-01/12/2014. 1.827.081 €. Co-ordinator.
- 11 U.E. 037611, EUROPRIME: EUROPEAN VACCINES AND MICROBICIDES ENTERPRISE. Research topic addressed: LSH-2005-2.3.0-2 UE. JOSÉ ALCAMÍ. (Instituto de Salud Carlos III). 01/02/2007-31/01/2012. 195.000 €.

## C.3. Participation in R&D and Innovation contracts

- 1 EVALUACIÓN DE LA ACTIVIDAD FRENTE AL VIRUS DE LA INMUNODEFICIENCIA HUMANA DE EXTRACTOS DE CIANOBACTERIAS. VALORALIA I MAS D SL. José Alcamí Pertejo. 01/01/2014-01/01/2017. 66.000 €.
- 2 ESTUDIO DE LAS CARACTERÍSTICAS DE VIRUS FUNDADORES EN UNA MUESTRA DE PACIENTES CON INFECCIÓN AGUDA POR EL VIH-1. Gilead Sciences, S.L.. José Alcamí Pertejo. 01/09/2013-01/09/2014. 49.500 €.
- 3 DESARROLLO DE UN MICROBICIDA VAGINAL FRENTE AL VIH SEPROX BIOTECH. ALCAMI JOSE. 01/06/2012-01/06/2014. 40.000 €.

- 4 ESTUDIO DE LA CAPACIDAD ANTIVIRAL DE DERIVADOS DE APRIDINA ZELTIA. José Alcamí Pertejo. 01/12/2004-01/12/2005.

#### C.4. Patents

- 1 GALLEGO José; PRADO JOSÉ; ALCAMI JOSE. PCT/ES2019/070440. COMPOUNDS FOR THE TREATMENT OF HIV INFECTION AND OTHER DISEASES CAUSED BY RNA VIRUSES Spain. 02/01/2020. Universidad Católica de Valencia San Vicente Mártir INSTITUITO DE SALUD CARLOS III.
- 2 GALLEGO JOSE; GONZALEZ LUIS; IBAÑEZ JOSE; ALCAMI JOSE; CATALAN JOSE. P201330235. NUEVOS P-TERFENILOS HEXAKIS-SUSTITUIDOS CON GRUPOS BILATERALES PARA EL TRATAMIENTO DE LA INFECCIÓN POR EL VIRUS DE LA INMUNODEFICIENCIA HUMANA TIPO 1 (VIH-1) Y OTRAS ENFERMEDADES. Spain. 21/02/2013. Instituto de Salud Carlos III, UNIVERSIDAD CATOLICA DE VALENCIA.
- 3 GOMEZ-ACEBO EDUARDO; ALCAMI JOSE. PCT/EP2010/068673. TOPICAL USE OF HYDROXYTYROSOL AND DERIVATIVES FOR THE PREVENTION OF HIV INFECTION. Spain. 2010. SEPROX BIOTECH S.L. SEPROX BIOTECH.
- 4 PCT/EP2010/062174. CYCLODEPSIPEPTIDE ANTIVIRAL COMPOUNDS 2009. PHARMAMAR S.A., ISCIII, Alcami J, Bedoya LM, Cuevas, MC.. Pharma Mar, S.A.